|
|
|
| Analysis of Clinicopathological Features of Different Subtypes of Papillary Thyroid Micro Carcinoma |
| DONG Xiao-feng, YANG Cong-ying |
| Department of Pathology,The Hospital of Lianyungang Traditional Chinese Medicine, Lianyungang 222004, China |
|
|
|
|
Abstract 【Objective】To explore the clinicopathological features of patients with different subtypes of papillary thyroid micro carcinoma (PTMC). 【Methods】A total of 367 patients with different subtypes of PTMC who were treated in our hospital from January 2010 to March 2018 were enrolled. The patients were observed for lesion size, calcification, extra-glandular microinfiltration, lymph node metastasis and Hashimoto's thyroiditis. Univariate and multivariate logistic regression analysis evaluated the influencing factors of lymph node metastasis in patients with PTMC. 【Results】Among all patients, there were 166 cases of columnar cell subtype PTMC, accounting for 45.2%; 152 cases of follicular subtype PTMC, accounting for 41.4%; 49 cases of other subtypes, containing 35 cases of intracapsular subtype, 8 cases of Warthin tumor-like subtype, 1 case of acidophilic subtype, 1 case of trabecular subtype and 4 cases of high cell subtype PTMC. Follicular subtype PTMC had the largest lesion diameter. Other subtypes of PTMC had the highest calcification rate and no extra-glandular infiltration. The lymph node metastasis rate of columnar cell subtype PTMC patients was significantly higher than that of follicular subtypes and other subtypes. Multivariate logistic regression analysis showed that males, younger than 50 years old, lesion calcification and extra-glandular infiltration were independent risk factors for PTMC lymph node metastasis. 【Conclusion】PTMC is mainly composed of columnar cell subtypes and follicular subtypes. The clinicopathological characteristics of PTMC in different subtypes are varied. Being male, age less than 50 years old, lesion calcification and extra-glandular infiltration are independent risk factors for PTMC lymph node metastasis.
|
|
Received: 26 September 2018
|
|
|
|
|
|
[1] 李徐恩,龚利挺.可外科治疗甲状腺微小乳头状癌的临床病理特点研究[J].现代实用医学,2017,29(8):1033-1035.
[2] Miyauchi A. Clinical trials of active surveillance of papillary microcarcinoma of the thyroid[J].World J Surg,2016, 40(3): 516-522.
[3] Sak SD. Variants of papillary thyroid carcinoma: multiple faces of a familiar tumor[J].Turk Patoloji Derg,2015, 31(Suppl 1): 34-47.
[4] Haugen BR, Alexander EK, Bible KC,et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016, 26(1): 1-133.
[5] Hay ID,Hutchinson ME,Gonzalez-losada T, et al. Papillary thyroid microcarcinoma : a study of 900 cases observed in a 60 year period[J].Surgery,2008, 144(6): 980-988.
[6] Lim JY, Hong SW, Lee YS, et al. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center[J].Thyroid,2013, 23(11): 1423-1430.
[7] Pisanu A, Deplano D, Reccia I, et al. Encapsulated papillary thyroid carcinoma: is it a distinctive clinical entity with low-grade malignancy[J].J Endocrinol Invest,2013, 36(2): 78-83.
[8] Oda H,Miyauchi A,Ito Y, et al. Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery[J].Thyroid,2016, 26(1): 150-155. |
|
|
|
2019, Vol. 36 
